Credit Suisse Reaffirms Outperform (N/A) Rating on Medivation (MDVN)

By admin | 6 years ago

Medivation (NASDAQ: MDVN)‘s stock had its “outperform (n/a)” rating restated by equities researchers at Credit Suisse (NYSE: CS) in a report issued on Monday.

Medivation opened at 81.64 on Monday. Medivation has a 52-week low of $14.32 and a 52-week high of $89.46. The company’s market cap is $2.959 billion.

Medivation last posted its quarterly earnings results on Tuesday, May 8th. The company reported $0.01 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.19 by $1.18. Medivation’s revenue was up 150.3% compared to the same quarter last year. Analysts expect that Medivation will post $-0.70 EPS next quarter.

Other equities research analysts have also recently issued reports about the stock. Analysts at Citigroup (NYSE: C) reiterated a “buy” rating on shares of Medivation in a research note to investors on Monday. They now have a $129.00 price target on the stock. Separately, analysts at Wedbush reiterated an “outperform” rating on shares of Medivation in a research note to investors on Monday. They now have a $100.00 price target on the stock, up previously from $86.00. Finally, analysts at Brean Murray reiterated a “buy” rating on shares of Medivation in a research note to investors on Monday.

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of small molecule drugs to treat serious diseases for which there are limited treatment options.

About the author